Welcome to our dedicated page for NH news (Ticker: NH), a resource for investors and traders seeking the latest updates and insights on NH stock.
NantHealth (NH) delivers innovative healthcare solutions through its unique integration of advanced diagnostics and comprehensive data analytics. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's progress in precision medicine.
Access timely reports on clinical developments, technology partnerships, and operational milestones that shape NH's position in healthcare innovation. Our curated collection includes earnings announcements, regulatory filings, product launch details, and strategic collaborations within the medical technology sector.
Key areas of coverage feature NH's systems-based approach to treatment optimization, advancements in biometric data integration, and initiatives supporting value-based care models. Stay informed about developments impacting personalized healthcare delivery and diagnostic technology evolution.
Bookmark this page for streamlined access to verified NH updates. Check regularly for new insights into how the company continues bridging healthcare services with actionable data solutions.
NantHealth has entered into a partnership with Care Continuity Inc. to enhance care logistics for patients with complex diseases, particularly focusing on cancer care pathways. The collaboration utilizes NantHealth's Eviti Connect platform, aiming to improve patient navigation through healthcare services. Key features include emergency discharge programs, inpatient discharge services, and high-touch care management. This partnership addresses challenges in patient self-navigation, ultimately striving for equal access to high-quality healthcare.
NantHealth (NASDAQ: NH) announced that Dr. Tiffany Avery will present at the Oncology Clinical Pathways Congress 2021 on October 1, 2021. Her session, titled Utilizing Pathways to Advance Equity in Cancer Care, will focus on promoting equity in oncology and addressing biases in cancer treatment. Dr. Avery aims to highlight the importance of transparency in treatment options and the need for equitable patient care across diverse demographics.
NantHealth (NASDAQ: NH) has partnered with Intraprise Health to enhance HIPAA compliance solutions for healthcare providers. This collaboration will integrate Intraprise Health’s HIPAA One Security Risk Assessment software into NantHealth’s NaviNet platform. Over 64,000 providers utilize Intraprise Health’s software, which offers automated compliance gap assessments and tracking. The partnership aims to simplify compliance with evolving regulations, benefiting healthcare practices by ensuring patient data security.
NantHealth, Inc. (NASDAQ-GS: NH) reported its Q2 2021 financial results, showing total net revenue of $16.1 million, a decrease from $17.6 million in Q2 2020. Gross profit was $9.1 million, representing 56% of revenue, down from 58% year-over-year. The company recorded a net loss of $15.3 million ($0.13 per share), significantly reduced from a loss of $48.3 million ($0.44 per share) in the same quarter last year. Cash reserves improved to $52 million following a $137.5 million financing transaction in April, enabling ongoing investments in product enhancements and capabilities.
NantHealth (NASDAQ: NH) has appointed Dr. Tiffany Avery as the new Chief Medical Officer, effective immediately. Dr. Avery's role will focus on providing clinical strategic direction and enhancing NantHealth’s Eviti decision support platform. With a strong background in oncology and epidemiology, she aims to improve health outcomes and address health disparities. Dr. Avery has been part of NantHealth since 2019, previously working in oncology at prominent institutions. Her expertise in cancer prevention and treatment will support the company's mission of delivering equitable healthcare.
NantHealth, Inc. (NASDAQ-GS: NH) will report its financial results for Q2 2021 on August 5, 2021, after market close. The management will host a conference call at 1:30 p.m. PT to discuss the company's performance. Interested parties can access the conference call by dialing 800-582-4096 (U.S./Canada) or 212-231-2918 (international). The call will also be broadcasted live on the NantHealth website.
NantHealth, Inc. (NASDAQ-GS: NH) reported first-quarter financial results for 2021, highlighting a revenue decline to $16.2 million from $18.2 million in Q1 2020. The company completed a $137.5 million financing to retire existing convertible notes and support growth in SaaS offerings and data services. R&D expenses increased to $5 million, contributing to a net loss of $15.4 million, or $0.14 per share. The launch of Eviti Connect for autoimmune diseases and expansion of OpenNMS offerings are key initiatives, aiming to broaden their business scope beyond healthcare.
NantHealth, a provider of enterprise solutions, has launched Eviti Connect for autoimmune diseases, a tool designed to help payers and providers manage treatment costs effectively. This expansion aims to benefit the approximately 50 million people in the U.S. living with autoimmune diseases, with annual treatment costs around $100 billion. Eviti Connect has previously supported over 345,000 cancer patients, yielding substantial savings for payers. The new platform is expected to streamline authorization workflows and enhance treatment decision-making in complex healthcare scenarios.
NantHealth, Inc. (NASDAQ-GS: NH) is set to release its financial results for Q1 2021 on May 6, 2021, after market close. The management will conduct a conference call at 1:30 p.m. PT (4:30 p.m. ET) to discuss performance details. Interested parties can join the call via phone or listen online at nanthealth.com.
NantHealth specializes in enterprise solutions for transforming complex data into actionable insights across various sectors, including healthcare and logistics.
NantHealth announced a financing deal involving the issuance of $137.5 million in senior unsecured convertible notes due 2026, aimed at enhancing financial flexibility and funding growth initiatives. The proceeds will retire existing convertible notes and support investments in businesses like NaviNet and Eviti, as well as the OpenNMS subsidiary. The deal is backed by existing investors Highbridge Capital and Nant Capital, with expected closing on or before April 27, 2021. The notes carry a 4.5% interest rate, paid semiannually, unless converted to stock.
